Peptide research, unfiltered
Read the research. Ignore the hype.
LetsTalkPeps is RN-reviewed peptide intelligence for biohackers, clinicians, and longevity scientists. Every claim is cited to primary literature and graded by how strong the evidence really is.
Evidence tiers
- Human RCT
Human RCT
Randomized controlled trials in humans
- Human data
Human data
Observational or mechanistic human studies
- Preclinical
Preclinical
Animal, cell, or in-silico models
- Anecdotal
Anecdotal
Case reports or community experience
Lead signal
research
GLP-1 Combinations: What Asian T2D Data Show
A 2025 review examines GLP-1 combinations with basal insulin in Asian adults with type 2 diabetes—what the data show on efficacy, safety, and dosing.
Ian Gauntt, RN BSN · September 18, 2026 · 12 min read
Latest signals
View all →
decision-framework
FDA uses AI to flag peptide vendors labeled ‘research use only’
Ian Gauntt, RN BSN · Sep 18, 2026 · 3 min
FDA deploys AI surveillance to flag peptide vendors whose “research use only” labels mask human‑use claims, prompting warning letters and enforcement actions.
pharmacokinetics
Oral peptide bioavailability: what research shows
Ian Gauntt, RN BSN · Sep 17, 2026 · 14 min
Oral peptide bioavailability is notoriously low. Recent preclinical and formulation research explains why—and what scientists are testing to fix it.
guides
Exendin-4 Bone Loss: What New Research Shows
Ian Gauntt, RN BSN · Sep 16, 2026 · 12 min
A 2025 preclinical study tested local exendin-4 bone loss prevention around implants. Here is what the animal data found and what remains unknown.
fundamentals
IL-31 and itch: what atopic dermatitis research shows
Ian Gauntt, RN BSN · Sep 15, 2026 · 13 min
IL-31 and itch drive the misery of atopic dermatitis. Here is what preclinical and clinical research reveals about the neuroimmune pathway and nemolizumab.
decision-framework
Emideltide (DSIP) Falls Short in FDA Compounding Vote
Ian Gauntt, RN BSN · Sep 15, 2026 · 2 min
FDA advisory panel rejected emideltide (DSIP) from the 503A compounding list citing safety, route mismatch, and poor characterization. Highlights evidence thresholds.
decision-framework
Peptide fertility strategies: what research shows
Ian Gauntt, RN BSN · Sep 12, 2026 · 13 min
Peptide fertility strategies are emerging to counter TRT-induced suppression. Here's what a 2025 narrative review found in preclinical and clinical data.
Peptide monographs
Cited profiles with evidence tiers and pharmacology notes.
growth
Human RCTACE-031
ACE-031 is a soluble activin receptor type IIB-Fc fusion protein that inhibits myostatin and related ligands. It has been tested in randomized trials for muscular dystrophy but is not approved for any use.
metabolic
PreclinicalAOD-9604
AOD-9604 is a synthetic peptide corresponding to amino acids 177-191 of human growth hormone. It has been investigated for fat metabolism in animals but has no established human efficacy for weight loss and is not approved by major regulators.
immune
Human RCTARA-290
ARA-290 (cibinetide) is an 11-amino-acid peptide that selectively activates the innate repair receptor. It has shown promise in Phase 2 trials for neuropathy and sarcoidosis-related fatigue but is not yet approved.
skin
Human dataArgireline
Argireline is a cosmetic peptide that inhibits SNARE complex formation and is marketed as a topical alternative to botulinum toxin for expression lines. Human cosmetic studies suggest modest wrinkle-reducing effects.
Newsletter
Get the signal before it gets noisy
New peptide research, decoded and cited. No marketing, no clinic spam.